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Through rapid genetic adaptation and natural selection, the Plas-
modium falciparum parasite|the deadliest of those that cause
malaria|is able to develop resistance to antimalarial drugs, thwart-
ing present eorts to control it. Genome-wide association stud-
ies (GWAS) provide a critical hypothesis-generating tool for under-
standing how this occurs. However, in P. falciparum, the limited
amount of linkage disequilibrium (LD) hinders the power of tradi-
tional, array-based GWAS. Here, we demonstrate the feasibility and
power improvements gained by utilizing whole-genome sequencing
for association studies. We analyze data from 45 Senegalese para-
sites and identify genetic changes associated with the parasites in
vitro response to twelve dierent antimalarials. To further increase
statistical power, we adapt a common test for natural selection,
XP-EHH, and utilize it to identify genomic regions associated with
resistance to drugs. Using this sequence-based approach and the
combination of association and selection-based tests, we detect sev-
eral loci associated with drug resistance. These include the pre-
viously known signals at pfcrt, dhfr, and pfmdr1, as well as many
genes not previously implicated in drug resistance roles, including
genes in the ubiquitination pathway. Based on the success of the
analysis presented in this study, and on the demonstrated shortcom-
ings of array-based approaches, we argue for a complete transition
to sequence-based GWAS for small, low-LD genomes like that of
P. falciparum.
GWAS j sequencing j EMMA j XP-EHH j malaria j drug resistance
Abbreviations: GWAS, genome-wide association study; LD, linkage disequilibrium;
SNP, single nucleotide polymorphism; EMMA, ecient mixed-model association; XP-
EHH, cross-population extended haplotype homozygosity
T
he malaria parasite Plasmodium falciparum imposes a
tremendous disease burden on human societies and is re-
sponsible for 1.2 million deaths annually (1). Current eorts
to eradicate malaria depend on the continued success of anti-
malarial drugs (2); however, the emergence of drug resistant
parasites threatens to hamper global health eorts to control
and eliminate the disease. Understanding the genetic basis of
these adaptations will be necessary to maintain eective global
health policies in the face of an ever-changing pathogen.
A key to elucidating the genetic basis of drug resistance is
identifying the specic genes associated with the phenotype.
In human studies of this kind, the genome-wide association
study (GWAS) has overtaken the classic candidate gene ap-
proach, made aordable by the use of genotyping arrays (or
SNP arrays) that measure only a subset of variants in the
genome (3). This optimization is only possible because of the
extensive correlation between genetic markers (called \linkage
disequilibrium" or LD) in the human genome, which allows
the subset of SNPs on an array to act as proxies for other
markers not present; this process is known as \tagging" (4).
In P. falciparum, however, array-based GWAS is severely
limited by the relatively short extent of LD (5{8). Lacking
that correlation between genetic markers, genotyping arrays
usually cannot detect associations with untyped markers, ef-
fectively limiting inferences to markers actually present on
the array; even the highest density P. falciparum array re-
ported to date found that LD between adjacent markers on
the array was too weak for tagging in African populations (6).
Consequently, current P. falciparum arrays cannot condently
capture all causal variants for important phenotypes.
The rapidly decreasing cost of whole-genome sequencing
oers a promising solution. In principle, working with whole
genome sequence allows one to directly assay all mutations
segregating in the population, obviating the detection prob-
lems associated with short LD. Discovering mutations directly
also avoids the ascertainment bias inherent to arrays|bias
that is exacerbated when SNP discovery and genotyping are
performed in dierent populations (9). Additionally, the small
size of the P. falciparum genome (23Mb, roughly the size of
a human exome), makes it potentially a hundred fold cheaper
than whole-genome sequencing in humans. As malaria se-
quencing projects become cost-competitive with genotyping
arrays, whole-genome sequencing has the potential to become
the most eective approach to performing association studies
in malaria.
Here, we test the hypothesis that whole-genome sequenc-
ing will identify SNP associations not detected by classic
array-based approaches. We apply this method to identify
loci in the P. falciparum genome that are associated with anti-
malarial drug resistance and compare the approach to a stan-
dard array-based GWAS. We improve the statistical power
of this analysis by adapting a commonly used selection test,
the cross-population extended haplotype homozygosity (XP-
EHH) test (10), and utilize it as an association test for posi-
tively selected phenotypes. These approaches identify a num-
ber of candidate loci associated with anti-malarial drug resis-
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ing that alteration of the parasites ability to modulate stress
may contribute to evasion of drug pressure and development
of resistance in P. falciparum.
Results
45 Parasite Genomes and the Absence of LD.We chose a
population in a West African region near Dakar, Senegal and
culture-adapted 45 Plasmodium falciparum parasites recently
isolated from malaria infected patients. This population is
particularly relevant for these studies as it has recently been
exposed to multiple, changing drug regimens as clinical re-
sistance to traditional drugs has emerged (11). We obtained
whole-genome sequence data and generated high-quality con-
sensus base calls for an average of 83% of each genome. This
produces 225,623 segregating single nucleotide polymorphisms
(SNPs), of which 25,757 met our call rate and minor allele
frequency criteria for further study (see Methods). Sequence-
based SNP calling in P. falciparum is technically challeng-
ing due to its extremely AT-rich genome (12,13). In light of
this, we validated our sequence-based approach against array-
based methods by using a previously described SNP array (6)
to genotype 24 of the 45 isolates. Of the 74,656 SNPs as-
sayed by the array, 4,653 meet our call rate and minor allele
frequency criteria. We observe nearly perfect concordance
between Aymetrix genotypes and sequence genotypes (see
Methods).
Our data demonstrate that SNPs in P. falciparum have
very little ability to tag neighboring SNPs due to the short
LD in the African population from which they were sampled.
While some portions of the genome exhibit signicant LD,
over 62% of the SNPs in the genome have no LD (r
2 < 0:05)
between adjacent SNPs, and 87% of the SNPs have insucient
LD to tag their neighbor (Fig. 1A) using the criterion derived
from human GWAS (r
2 < 0:8) (4). To measure tagging abil-
ity directly, we simulate genotyping arrays of various sizes by
sampling random subsets of SNPs from our sequence data.
We nd that the simulated arrays are not able to tag a signif-
icant portion of unassayed markers, a result in stark contrast
to the performance of human arrays (Fig. 1B). The tagging
performance of our own Aymetrix array (tagging only 22.6%
of segregating SNPs in Senegal) is even lower than simulated
arrays of similar size (Fig. 1B), most likely due to population-
based ascertainment biases (9) that were not modeled in our
idealized approach. These ndings lead us to conclude that
array-based studies in P. falciparum will rarely be able to de-
tect signals resulting from mutations not present on the array.
Sequence-based Genome-wide Association Studies. The goal
of these studies is to identify genomic changes associated with
changes in parasite response to antimalarial drugs, as mea-
sured in the set of 45 independent P. falciparum isolates.
We assayed the cultured parasites for in vitro drug responses
(measured by IC50) to twelve standard antimalarials: amodi-
aquine, artemisinin, atovaquone, chloroquine, dihydroartemis-
nin, halofantrine, lumefantrine, meoquine, piperaquine, pri-
maquine, pyrimethamine, and quinine. These constitute the
twelve phenotypes used in our association studies (Fig. S1).
Not surprisingly, drugs with similar chemical structures (e.g.
halofantrine, lumefantrine, and meoquine) show a strong cor-
relation in responses (Fig. S2), as has previously been ob-
served (6,7), and provide the opportunity for cross-validation
of SNPs identied in association studies.
To test associations between SNP genotypes and drug re-
sponse, we use ecient mixed-model association (EMMA).
EMMA is a quantitative association approach well-suited for
small sample sizes and partially inbred organisms, such as
the malaria parasite (14). It is a commonly used tool among
mixed-model GWAS approaches (15) and has recently demon-
strated eectiveness with P. falciparum drug studies (6). Af-
ter correcting for multiple testing (Bonferroni correction for
25,757 SNPs, P < 210
 6), EMMA is able to detect a number
of previously known markers of drug resistance, such as four
non-synonymous SNPs in pfcrt (16,17) associated with chloro-
quine response (N75E/K, K76T, Q271E, R371I), one pfmdr1
SNP (18,19) associated with halofantrine, lumefantrine, and
meoquine response (N86Y), and three dhfr SNPs (20) asso-
ciated with pyrimethamine response (N51I, C59R, S108N).
We note here that, although mitochondrial and apicoplast
genomes were also sequenced, no signicant associations were
found and the known mitochondrial mutations associated with
atovaquone resistance (21,22) were xed in all 45 individu-
als for the drug-sensitive alleles (cytochrome b 268Y, 133M,
280G). In all, EMMA detects 34 signicant SNPs associated
with parasite response to ve drugs (Fig. S3). Most are in
or near previously known associations (8), and ve are novel
associations with pyrimethamine response (Supp File S6).
While these sequence-based ndings validate the previ-
ously known relationship between the pfmdr1 gene and para-
site responses to halofantrine, lumefantrine, and meoquine,
it is notable that this association is not detectable by our
SNP array (Fig. 2, Fig. S5), as the array lacks any mark-
ers in pfmdr1 with a suciently high minor allele frequency.
This exemplies the type of association that can be missed
by arrays due to limited LD. Additionally, the agreement be-
tween these three drugs at this locus provides validation of
this result with respect to structurally related drugs.
Using Haplotype-based Selection Tests for Association.To
test the hypothesis that drug resistance is largely driven by
positive selection, we searched for long haplotypes associated
with selection for drug resistance using the XP-EHH test (10).
This selection test has not previously been used as a GWAS
tool, but it is well suited for this purpose when we presume
that the phenotype we are studying is under positive selec-
tion. While this assumption is not valid for most human-
based GWAS for non-communicable diseases, it is very likely
to be the case when studying parasite genomes for resistance
adaptations to widely used drugs, which represent a strong
selective pressure. Used in this way, the XP-EHH test identi-
es areas in the genome where resistant parasites show much
longer haplotypes than sensitive parasites, indicative of recent
positive selection on the resistant population. In our data, the
test detects a number of signals, including pfcrt and dhfr, as
well as a number of other hits spanning a total of 32 genomic
regions across eleven drugs (Fig. 3, Fig. S4, Supp File S6).
Seventeen of these regions are indicative of selection in the
drug resistant population, whereas fteen are consistent with
selection in the drug sensitive population. With the excep-
tion of the regions containing pfcrt and dhfr, none of these
loci were detected by EMMA alone.
While this approach does not detect the known pfmdr1 lo-
cus, this is consistent with our expectations, due to the nature
of the test. The N86Y mutation in pfmdr1 confers increased
susceptibility (18,19) to many drugs when compared to the
wild-type allele. As such, this SNP would not be an expected
candidate for positive natural selection on a novel variant|
the type of selection XP-EHH is designed to detect. Moreover,
the absence of a pfmdr1 signal from the XP-EHH test is con-
sistent with the lack of ndings in this gene from previous
genomic scans for positive selection based on the REHH, iHS,
and XP-EHH tests in multiple populations (5,6,23).
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ically identies a large number of signicant SNPs in close
proximity to each other. These regions often span many
tens of kilobases and several annotated genes. This is ex-
pected because the process of positive natural selection in-
creases the prevalence of both the selected variant as well as
of nearby variants, generating local regions of extended hap-
lotypes. Thus, while XP-EHH strongly implicates these 32
regions as areas of phenotype-associated positive selection, by
itself it is usually unable to localize the source of this selection
to a specic gene. We use P-values from EMMA to improve
signal localization by identifying the strongest signals of asso-
ciation within each region. This approach allows us to suggest
a possible gene or mutation as a focus of phenotype-specic
positive selection for each identied region (Supp File S6) and
is reminiscent of earlier approaches that intersect selection and
association results (23,24).
A more comprehensive examination of the regions un-
der drug-associated selection reveals discrete biological path-
ways and processes that may be particularly important as
mediators of drug response in P. falciparum (Supp Results).
The 59 genes in these 32 regions can be functionally clas-
sied as: surface molecules or transporters, genome main-
tenance or transcriptional regulation, metabolic enzymes in-
cluding lipid metabolizers, and members of the ubiquitin pro-
teasome system. Most surface molecule associated mutations
and intergenic mutations are localized to intra-chromosomal
clusters containing var, rin and stevor genes; and a num-
ber of genes are found among molecules modulating ubiqui-
tination, lipid metabolism, or folate metabolism. Members
of these pathways are also represented in the large region of
pyrimethamine-specic selection on chromosome 6, where it
is dicult to localize the focus of selection. Collectively, these
ndings argue that certain biological processes in general, and
genes in the ubiquitination and lipid metabolism pathways in
particular, play important roles in modulating drug responses
in P. falciparum.
Discussion
Complete genome sequencing provides many advantages over
array-based genotyping for association studies. These include
the ability to directly type the causal allele, the increased de-
tection power from increased marker density, and the ability
to overcome ascertainment biases that arise when studying
dierent populations with a xed marker set. In P. falci-
parum, the lack of tagging ability due to the near absence
of long-range LD limits the utility of arrays for association
studies. Furthermore, the small genome size of P. falciparum
brings the cost of whole genome sequencing to approximate
parity with traditional genotyping arrays, and recent advances
in pathogen-specic DNA-enrichment and host-specic DNA-
depletion techniques for clinical samples makes the sequence-
based GWAS approach more accessible and cost-eective than
ever before (13,25).
We introduce a selection-association approach based on
the XP-EHH selection test. While this approach may not
be appropriate for many association studies, it is sensible
when the phenotype under study is under strong selection,
which is likely the case for drug resistance in pathogens. As
a haplotype-based test that takes advantage of multiple, ad-
jacent SNPs, it has the advantage of being more sensitive
than single-marker approaches like EMMA, given the same
sample size (4). In addition to detecting new signals of drug-
associated selection, we also nd that the directional nature
of the test statistic, a Z-score, provides useful information
about whether the selection is associated with drug sensitiv-
ity or resistance. Consequently, we also introduce an alter-
native visualization of the output: a Manhattan-like plot of
Z-scores, instead of  log10 P-values, to illustrate the direc-
tionality of the signals (Fig. 3). In our data, we observed
a tendency for many drugs (artemisnin, dihydroartemisnin,
primaquine, halofantrine, lumefantrine, and meoquine) to
show highly signicant signals of selection for drug sensitiv-
ity at pfcrt, the gene known to be responsible for chloroquine
resistance (Fig. S4). While, in principle, this type of signal
may result from selection towards drug sensitivity, in this par-
ticular case, it most likely results from the general pattern of
anti-correlation between chloroquine and these six other drugs
(Fig. S2). Additionally, the absence of a signicant chloro-
quine sensitivity signal at pfcrt is consistent with reports that
the return of chloroquine sensitive parasites in Africa did not
result from a classic selective sweep (26). In either case, the
Manhattan-like Z-score plots allow us to note the presence
of these drug sensitivity signals while keeping them visually
separate from the drug resistance signals on which we wish to
focus.
Our approaches identify a signicant number of loci as-
sociated with changes in drug response (Supp File S6). The
strongest of these contain previously known mediators of re-
sistance, such as the mutations in pfcrt, pfmdr1, and dhfr. Cu-
ration of our remaining results using a variety of gene and pro-
tein prediction algorithms and literature searches (27) point to
several cellular processes and pathways of potential interest,
including the ubiquitin proteasome system, lipid metabolism,
and folate metabolism (Supp File S6). We argue that these
ndings point to biological processes used by the parasite
to survive drug pressure or circumvent the action of anti-
malarial compounds. Other genes of interest include three
ABC transporters|a class of transporters known to modulate
drug responses in other organisms (28)|and genes proposed
to modulate chromatin (29,30), DNA repair (31,32), or RNA
binding (33)|pathways that have been shown to potentially
be altered in response to drug pressure.
A number of the signals of recent positive selection
are unique to pyrimethamine-resistant parasites. While the
known resistance locus, dhfr, is present among these, there
are even stronger signals of pyrimethamine-associated selec-
tion on chromosome 6 and chromosome 12. The region on
chromosome 6 contains two previously uncharacterized genes
proposed to participate in folate metabolism (PFF1360w and
PFF1490w), as well as six genes acting as either chaper-
ones or in ubiquitination (PFF1365c, PFF1485w, PFF1445c;
PFF1415c; and PFF1505w), and three molecules likely to
modulate lipid metabolism (PFF1350c, PFF1375c-a/b, and
PFF1420w). In the chromosome 12 region, the XP-EHH test
produces signicant P-values for eight SNPs over a 15kb re-
gion spanning ve adjacent genes. The extended haplotypes
surrounding these SNPs continue even further, spanning 28kb
and fourteen genes in total (Fig. 4A). These results present
challenges for experimental validation, as the goal of associ-
ation studies is to generate a small number of testable hy-
potheses about molecular mechanisms. Fortunately, the use
of EMMA P-values in this region can assist in localizing the
signal. We nd that the strongest EMMA SNP coincides with
the strongest XP-EHH SNP, which is a non-synonymous mu-
tation in PFL2100w, a putative ubiquitin conjugating enzyme
(E2) (Fig. 4B). Additionally, a signicant, pyrimethamine-
specic selection signal on chromosome 8 is entirely contained
within MAL8P1.23 (a putative HECT ubiquitin ligase E3)
(Supp File S6), another gene in the ubiquitin-mediated path-
way (34). Given the role of this pathway in directing pro-
tein degradation and recycling, it is possible that alterations
in these genes create changes in stress responses or protein
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to survive under drug pressure.
The evolution of drug resistance in the natural setting
is likely to be a multistep process and our work potentially
identies key pathways involved in this process. Field-based
evidence has demonstrated a reduced tness for drug resis-
tant parasites in the absence of drug pressure and laboratory-
based work has demonstrated the relative tness of dierent
mutational changes in target enzymes. Our ndings point
to potential compensatory mutations in a pathway related to
protein stability and turnover and it is tempting to speculate
that such adaptations enable the \expression" of a resistant
phenotype, such as has been observed in yeast (35). Although
molecular approaches are required to validate the role of this
pathway in modulating drug response, these results demon-
strate the potential for sequence-based GWAS approaches to
identify pathways, in addition to individual genes, that may
be responsible for the phenotype of interest.
Ultimately, all association results require experimental
validation and follow-up work to explore possible mechanisms
of action. Association studies, even in their ideal form, sim-
ply generate hypotheses based on correlations. However, im-
proved methods for association studies can signicantly re-
duce the necessary validation work by reducing false positive
rates, increasing study detection power, and improving local-
ization ability. This study successfully pilots the use of whole-
genome sequence data for association studies in malaria and
it demonstrates signicant advantages in detection power over
array-based studies. We strongly recommend that future as-
sociation studies in low-LD, small-genome organisms adopt
the sequence-based GWAS approach as well, given the rela-
tive costs. We additionally demonstrate the eectiveness of
the XP-EHH selection test as an association test for pheno-
types under positive selection. Finally, we combine data from
both tests to localize long signals and reduce the number of
hypotheses for follow-up validation. This combined approach
identies more candidate loci than with single-marker tests
alone.
Materials and Methods
Sequencing. Parasites were obtained from patients with uncomplicated mild malaria
in Senegal from 2001 to 2009 under ethical approval with informed consent for
the study. Parasites were culture adapted by standard methods (36) and genomic
DNA was extracted from 45 single-clone samples. Samples were determined to
be monoclonal and genetically distinct by a 24 SNP molecular barcode (37). Ge-
nomic DNA was sequenced using Illumina Hi-Seq machines. The rst 12 para-
sites were sequenced with 76bp single-end reads and the remaining 33 were se-
quenced with paired-end reads ranging from 76bp to 101bp in length. The me-
dian sequence coverage depth was 144.8X after alignment (ranging from 32X to
400X). Reads were aligned with BWA v0.5.9-r16 against the 3D7 reference as-
sembly (PlasmoDB v7.1). A consensus sequence was called for each strain us-
ing the GATK Unied Genotyper v1.2.3-g61b89e2 (38) with the following param-
eters: -A AlleleBalance -stand emit conf 0 --output mode
EMIT ALL SITES. Bases were then removed if they exhibited poor quality (GQ
less than 30 or QUAL less than 60) or if they called a heterozygous genotype. This left
consensus calls for 56-91% of the genome (83% median) for each of 45 individuals.
Of these sites, 225,623 positions are polymorphic among the 45 individuals. Of these
SNPs, only 25,757 had genotypes in at least 36 individuals (80% call rate) and were
non-singletons (i.e. minor allele count > 1 or minor allele frequency > 4%). All
analyses are based on this set of 25,757 SNPs. SNP data is available in dbSNP as
batch Pf 0004 from submitter BROAD-GENOMEBIO. SNPs are being processed at
PlasmoDB (27) for release later this year. SNP data can also be found in Supp File
S9. Consensus calls for the whole genome are available in Supp File S10.
Principal component analysis was conducted using the program SMARTPCA
(39) in the EIGENSOFT 3.0 package. We applied a local LD correction (nsnpldregress
= 2) and found no signicant eigenvectors in the population.
Tagging Analysis. Tagging analysis in Figure 1B was generated by using PLINK (40)
to nd tagging SNPs for each SNP that were within 10kb and at least r
2 >= 0:8.
We then simulated genotyping arrays by randomly sampling subsets of SNPs of varying
subset sizes and calculating the fraction of total SNPs that are tagged by the subset.
We rst reduced the sequence data to 40 random individuals to simulate ascertain-
ment bias against low allele-frequency markers, then randomly sampled markers that
were still polymorphic among the smaller population size to simulate a genotyping
array. We simulated 19 dierent array sizes, ranging from 5% of the sequenced SNPs
(1,227) to 95% of the sequenced SNPs (22,087). 200 simulations per array size were
run and the result was highly consistent: 95% condence intervals were too small to
visualize on the gure. Simulations for the human genome were based on 60 diploid
individuals of European descent (CEU) from Hapmap release 23a. Each iteration
chose 54 random individuals to simulate ascertainment bias, ltered SNPs to an 80%
call rate and to non-singletons. Our Aymetrix array was able to tag 5,508 SNPs in
our sequence data using the 4,894 SNPs on the array that overlapped with the 25,757
SNPs in our sequence data (open triangle in Fig 1b). Histograms in Figure 1A are
binned into 20 evenly spaced bins of r
2 from 0 to 1. The plot is normalized such that
the sum of all bars in each histogram is equal to 1 to show the relative proportions
of SNPs in each bin. Simulation data is provided in Supp File S7.
Drug Assays. Drug assays were performed as described (41) with slight modications
for 384-well format (Supp Methods). The range of drug concentrations are shown in
Figure S1, and the IC50 data is provided in Supp File S8. Raw input data for all
association tests is provided in Supp File S9.
EMMA. Single marker association tests were run using EMMA (14). Since not all
drugs have complete phenotype data for all 45 individuals, SNPs are additionally l-
tered to those that met our previous call rate and minor allele criteria among the
subset of samples for which drug data exists. This results in 23,000 to 25,180 SNPs
for any given drug. log10(IC50) values were used for this quantitative test. Bio-
logical replicates of drug data were presented to EMMA as multiple individuals from
the same genetic strain. This allows EMMA to use the additional data to discern
heritable phenotypic variance from non-heritable variance (15), and mimics the use
of clonally identical parasites in other studies (42,43). Signicance was dened as
SNPs that exceeded a Bonferroni-corrected threshold of P < 0:05 while also sur-
viving 60% of jackknife simulations. EMMA results were jackknifed by performing
200 random subsets of 38 samples and requiring an FDR-corrected signicance of
Q < 0:1. SNPs that passed this threshold in 60% of jackknife simulations were
considered to be robust against false positives due to small sample size eects.
XP-EHH. Selection-association tests were run using the cross population extended
haplotype homozygosity test (XP-EHH) (10). Each drug dened a partitioning of
samples into two \subpopulations" (\sensitive" and \resistant") based on cutos
shown in Figure S1 and Supp File S8 (Supp Methods). XP-EHH requires a recombi-
nation map as input, which we constructed with LDhat v2.1 (44) (Supp Methods).
XP-EHH also requires fully imputed genotypes. Imputation was performed using
PHASE 2.1.1 (45), producing 29,605 non-singleton SNPs (Supp Methods).
XP-EHH computes a signicance value for each SNP in the genome, assuming
that SNP comprises the haplotype \core" of selection. Because the test identies long
haplotypes, it results in a large number of genome-wide signicant SNPs (dened by
Bonferroni-corrected P < 0:05) in clustered stretches of the genome. We reduced
the set of signicant SNPs to a set of signicant genomic regions by taking each sig-
nicant core SNP, computing a window around each one where EHH decayed to 0.05,
and merging overlapping windows. This resulted in a smaller list of signicant regions
for each drug (Supp File S6). Regions were further ltered by removing those which
did not contain at least one core SNP that survived 50% of jackknife simulations.
XP-EHH results were jackknifed by performing 200 random subsets of 38 samples
and requiring a Bonferroni-corrected signicance of P < 0:1.
Genotyping Arrays. A subset of 25 parasites was also hybridized to an Aymetrix
array containing 74,656 markers (6). SNPs were called using BRLMM-P from Ay
Power Tools v1.10.2 and ltered according to the same methods as Van Tyne, et
al (6), resulting in 15,075 validated SNPs, 8,778 of which were polymorphic among
the 25 individuals from Senegal. SNP coordinates were converted from PlasmoDB
v5.0 coordinates to v7.1 coordinates using whole genome nucmer alignments (46).
Concordance between array and sequencing data was measured for the set of markers
in which genotype calls existed by both methods. For 24 samples, nearly perfect
concordance between Aymetrix genotypes and sequence genotypes was observed for
the 24 samples (averaging 99.2% concordance, with all 24 samples above 98.2% con-
cordance). This level of concordance is similar to what is observed with technical
replicate hybridizations of the same DNA sample (6). One sample, SenP19.04.c, re-
ported a 28.2% mismatch rate, suggestive of a sample identication error, and was
removed from the analysis. EMMA analyses were run on the array data using the
same lters and procedures as for sequence data described above, utilizing 4,514-
4,653 SNPs per drug phenotype. Results are shown in Fig S3. Array data for these
24 samples are in Supp File S9.
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Fig. 1. Simulated P. falciparum arrays are unable to tag SNPs not present on the array. (A) A histogram of LD between adjacent SNPs from sequenced P. falciparum
(black). The vast majority of markers have little to no LD with their neighbors (62% of SNPs have r2  0:05, 76% have r2  0:2, and 87% have r2  0:8). This
contrasts with human studies where much more of the genome shows moderate to strong LD between neighboring SNPs (gray). (B) Simulated genotyping marker sets of
various sizes are plotted against the percentage of the entire sequenced marker set that they are able to tag (with r2  0:8). The dashed, identity line depicts the theoretical
scenario where all SNPs are in complete linkage equilibrium and no SNP tags another. Since this is true of 87% of SNPs in the malaria sequence data, the increase is almost
linear (black dots). This contrasts with the array tagging performance seen in human studies (gray dots), where only a small fraction of markers are needed to tag the bulk
of the genome|a principle that array-based GWAS depends on. The open triangle depicts the actual performance of the Aymetrix-based Broad Institute P. falciparum SNP
array (6).
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Fig. 2. Meoquine association signals around the known drug resistance locus pfmdr1.
EMMA results are shown for all of chromosome 5 with P-values for each SNP on a  log10
scale against physical position. The array-based study (Array 24) does not detect any association
at the known pfmdr1 locus due to a lack of marker coverage within the gene and sucient LD
around the gene. The sequence-based study with the same 24 samples (Seq 24) detects the
expected hit at 0.96Mb. Including all samples from the sequence-based study (Seq 45) increases
the strength of this signal. The dashed line indicates the Bonferroni-corrected signicance
threshold (P = 0:05, genome-wide SNP counts are 7,068, 17,278, and 25,159 respectively).
Fig. 3. Signicant signals of drug-associated selection across ve antimalarial drugs. XP-
EHH results are shown using a Manhattan-inspired plot, with SNP Z-scores plotted against
genomic position, with each chromosome colored separately. Positive Z-scores suggest selection
in drug resistant parasites, negative Z-scores suggest selection in sensitive parasites. The dashed
lines indicate the two-sided Bonferroni signicance thresholds (P = 0:025 and 0:975). Only
drugs with signicant hits are shown here, Z-score and quantile-quantile plots for all drugs are
shown in Fig. S4.
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Fig. 4. Localizing the pyrimethamine-associated selection signal on chromosome 12. (A)
Dening the region: XP-EHH identies eight genome-wide signicant SNPs in close proximity
on chromosome 12. Each of these eight SNPs represents the center of an area of extended
haplotype homozygosity, as measured by the EHH statistic. Haplotype decay for resistant
parasites is plotted for each of these eight SNPs, which denes a larger region from 1.807Mb
to 1.835Mb in which the causal mutation may exist. This region spans 28kb and 14 genes.
(B) Localizing the signal: focusing within this region, we utilize single-marker association
signals from EMMA to localize the signal. The most signicant EMMA SNP coincides with
the most signicant XP-EHH SNP and localizes to an E398D mutation in PFL2100w (ubiquitin
conjugating enzyme E2).
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